Checkpoint Inhibitor Therapy for Patients with Immune-Mediated Inflammatory Diseases (Video)

Dr. Leonard Calabrese outlines a complex topic

Checkpoint inhibitor therapy for cancer holds great potential for durable response rates, but immune-related adverse events may be its Achilles’ heel. For the millions of individuals with immune-mediated inflammatory diseases (IMIDs), the safety of this therapy is especially in question. In this video, Leonard Calabrese, DO, Director of the RJ Fasenmyer Center for Clinical Immunology within the Department of Rheumatic and Immunologic Diseases, outlines the complexities of this therapy’s use in patients with IMIDs. The video is part of an editorial originally published in Annals of Internal Medicine.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy